HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway
Previous studies have demonstrated that intrahepatic cholangiocarcinoma (ICC) may derive from transdifferentiation of hepatocytes, so transforming ICC cells into hepatocytes could be a potential strategy for treating ICC. Hepatocyte nuclear factor 4α (HNF4α), a master transcription factor in the liv...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193652332500021X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850078966490071040 |
|---|---|
| author | Bo-Nan Xu Cheng-Hong Ding Yi-Long Liu Yuan-Yuan Luo Juan Deng Shu-Qing Liu Meng-Chao Xiao Nan Jiang Xin Zhang Wen-Ping Xu Wei-Fen Xie |
| author_facet | Bo-Nan Xu Cheng-Hong Ding Yi-Long Liu Yuan-Yuan Luo Juan Deng Shu-Qing Liu Meng-Chao Xiao Nan Jiang Xin Zhang Wen-Ping Xu Wei-Fen Xie |
| author_sort | Bo-Nan Xu |
| collection | DOAJ |
| description | Previous studies have demonstrated that intrahepatic cholangiocarcinoma (ICC) may derive from transdifferentiation of hepatocytes, so transforming ICC cells into hepatocytes could be a potential strategy for treating ICC. Hepatocyte nuclear factor 4α (HNF4α), a master transcription factor in the liver, has been demonstrated to induce the differentiation of hepatocellular carcinoma, while its effects on ICC remains unclear. Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor, is a novel targeted drug for ICC patients. However, drug resistance limits its clinical efficacy. In the present study, we found that the downregulation of HNF4α expression was associated with aggressive tumor behavior and poor prognosis in ICC patients. Upregulation of HNF4α inhibited proliferation, migration, invasion and colony-formation ability, increased the expression of hepatocyte functional genes in ICC cells in vitro, and suppressed the growth of subcutaneous tumors in vivo. Importantly, HNF4α adenovirus treatment significantly reduced the tumor burden of Akt/NICD-induced primary ICC in mice. Furthermore, HNF4α enhanced the sensitivity of ICC cells to ivosidenib both in vitro and in vivo. RNA sequencing revealed that HNF4α suppressed several cancer-related pathways, including Wnt signaling pathway. The agonist of Wnt signaling pathway partially blocked the inhibitory effect of HNF4α on the proliferation and resistance to ivosidenib of ICC cells. These results identify HNF4α as a tumor suppressor for ICC and a potential sensitizer to ivosidenib in ICC patients. The reintroduction of HNF4α might help achieve more effective and precise targeted therapy, benefiting the survival of patients with ICC. |
| format | Article |
| id | doaj-art-c99cbf0a718f4a6ebd6045c70d6ce362 |
| institution | DOAJ |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-c99cbf0a718f4a6ebd6045c70d6ce3622025-08-20T02:45:24ZengElsevierTranslational Oncology1936-52332025-03-015310229010.1016/j.tranon.2025.102290HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathwayBo-Nan Xu0Cheng-Hong Ding1Yi-Long Liu2Yuan-Yuan Luo3Juan Deng4Shu-Qing Liu5Meng-Chao Xiao6Nan Jiang7Xin Zhang8Wen-Ping Xu9Wei-Fen Xie10Department of Gastroenterology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai 200003, ChinaDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai 200003, ChinaDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai 200003, ChinaDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai 200003, ChinaDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai 200003, China; Corresponding authors.Department of Gastroenterology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai 200003, China; Corresponding authors.Previous studies have demonstrated that intrahepatic cholangiocarcinoma (ICC) may derive from transdifferentiation of hepatocytes, so transforming ICC cells into hepatocytes could be a potential strategy for treating ICC. Hepatocyte nuclear factor 4α (HNF4α), a master transcription factor in the liver, has been demonstrated to induce the differentiation of hepatocellular carcinoma, while its effects on ICC remains unclear. Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor, is a novel targeted drug for ICC patients. However, drug resistance limits its clinical efficacy. In the present study, we found that the downregulation of HNF4α expression was associated with aggressive tumor behavior and poor prognosis in ICC patients. Upregulation of HNF4α inhibited proliferation, migration, invasion and colony-formation ability, increased the expression of hepatocyte functional genes in ICC cells in vitro, and suppressed the growth of subcutaneous tumors in vivo. Importantly, HNF4α adenovirus treatment significantly reduced the tumor burden of Akt/NICD-induced primary ICC in mice. Furthermore, HNF4α enhanced the sensitivity of ICC cells to ivosidenib both in vitro and in vivo. RNA sequencing revealed that HNF4α suppressed several cancer-related pathways, including Wnt signaling pathway. The agonist of Wnt signaling pathway partially blocked the inhibitory effect of HNF4α on the proliferation and resistance to ivosidenib of ICC cells. These results identify HNF4α as a tumor suppressor for ICC and a potential sensitizer to ivosidenib in ICC patients. The reintroduction of HNF4α might help achieve more effective and precise targeted therapy, benefiting the survival of patients with ICC.http://www.sciencedirect.com/science/article/pii/S193652332500021XHepatocyte nuclear factor 4α (HNF4α)Intrahepatic cholangiocarcinoma (ICC)Wnt signaling pathwayIsocitrate dehydrogenase 1(IDH1) |
| spellingShingle | Bo-Nan Xu Cheng-Hong Ding Yi-Long Liu Yuan-Yuan Luo Juan Deng Shu-Qing Liu Meng-Chao Xiao Nan Jiang Xin Zhang Wen-Ping Xu Wei-Fen Xie HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway Translational Oncology Hepatocyte nuclear factor 4α (HNF4α) Intrahepatic cholangiocarcinoma (ICC) Wnt signaling pathway Isocitrate dehydrogenase 1(IDH1) |
| title | HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway |
| title_full | HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway |
| title_fullStr | HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway |
| title_full_unstemmed | HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway |
| title_short | HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway |
| title_sort | hnf4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the wnt signaling pathway |
| topic | Hepatocyte nuclear factor 4α (HNF4α) Intrahepatic cholangiocarcinoma (ICC) Wnt signaling pathway Isocitrate dehydrogenase 1(IDH1) |
| url | http://www.sciencedirect.com/science/article/pii/S193652332500021X |
| work_keys_str_mv | AT bonanxu hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT chenghongding hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT yilongliu hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT yuanyuanluo hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT juandeng hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT shuqingliu hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT mengchaoxiao hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT nanjiang hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT xinzhang hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT wenpingxu hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway AT weifenxie hnf4ainhibitsthemalignancyofintrahepaticcholangiocarcinomabysuppressingthewntsignalingpathway |